• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Will Novo cover Zepbound if Wegovy is unavailable?


<



Well since the obesity reps have nothing else to be doing but helping to get patients access to Zepbound, Novo might as well cover it and get some kind of return on their investment